AiCuris GMBH & Co. KG

With seven molecules in clinical development, another three preclinical compounds approaching the clinic, and a half-dozen discovery programs divided equally between virology and bacteriology, AiCuris is seeking the keys to thwarting viral replication. The start-up has drug candidates targeting herpes simplex virus, human cytomegalovirus and hepatitis C.